Chelsie Derman

Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.

Contrary to earlier research, a Framingham Heart Study analysis found no significant dementia risk tied to transient ischemic attack over 2 decades.

Transcend Therapeutics' TSND-201 gains FDA Breakthrough Therapy designation, offering new hope for rapid PTSD treatment with promising clinical trial results.

Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.

In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.

Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.

5 FDA updates in psychiatry from the first half of 2025, plus other pipeline developments in psychiatry for depression, schizophrenia, and OUD.

Key FDA approvals, clinical trial insights, and expert commentary in allergy care from the first half of 2025.

This Q2 psychiatry recaps promising data of COMP360 for treatment-resistant depression, the expansion of clozapine access, and experts weighing in on new data and ethical debates.

Q2 2025 allergy news highlights include FDA actions on HAE therapies, warnings for antihistamines, and new sinus surgery guidelines for chronic rhinosinusitis.

Breakthroughs in narcolepsy, idiopathic hypersomnia, OSA, and RLS signal a shift toward personalized care and novel therapies. Check out this June 2025 sleep month in review.

This month in review captures 5 allergy news in June, from FDA approvals to phase 3 data.

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

At SDPA 2025, Theodore Rosen, MD, discussed various psychological disorders, including delusions of parasitosis, excoriation disorder, dermatitis artefacta, and others.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

More than 60% of patients with psoriasis achieved PASI 100 at week 16 with bimekizumab and maintained skin clearance up to 4 Years.

Amlitelimab shows promise as a safe and effective treatment for moderate-to-severe atopic dermatitis, with sustained benefits post-treatment.

At SDPA 2025, Candrice Heath, MD, said many clinicians remain unaware of baby perfume traditions that may contribute to persistent symptoms in patients of color.

At SDPA 2025, Candrice Heath, MD, presented on what you can do in your clinic to bridge the gap in pediatric atopic dermatitis among children with darker skin tones.

A single 25 mg dose of synthetic psilocybin led to a significant reduction in depression severity at 6 weeks in the pivotal COMP005 trial for TRD, meeting its primary endpoint.

The monoclonal antibody garadacimab-gxii offers once-monthly, citrate-free dosing to prevent hereditary angioedema attacks in patients aged ≥ 12 years.

At SLEEP 2025, Axsome Therapeutics presented phase 3 ENCORE and SYMPHONY data showing AXS-12 reduced cataplexy attacks and improved daytime functioning in narcolepsy.

A recent study reveals how personality traits like neuroticism and extraversion influence bedtime procrastination in young adults, impacting sleep health.

Disrupted circadian rest-activity rhythms were tied to faster biological aging in older adults, independent of age, sex, or race, new study shows.

UK study finds atopic conditions, especially anaphylaxis, significantly raise the risk of anxiety, depression, OCD, and other mental illnesses in primary care patients.

Asthma and peanuts were identified as key risk factors for grade 4 anaphylaxis in a retrospective study, highlighting the need for tailored prevention.

A recent study reveals no link between cesarean delivery and childhood allergies, challenging previous findings and highlighting Japan's unique health context.

Check out these 7 late-breaking abstracts to watch at the upcoming SLEEP 2025 meeting.